RxDoctor Payments Data

Pallavi Gupta, MD

Interventional Pain Medicine · Austell, GANPI 1043503824

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,697 of the $7,516 with a category attached, or 89.1%. 45 manufacturers reported payments, led by Boston Scientific at 33.2% of the total. Reporting peaked in 2021 at $2,250 and has fallen 61.3% since, to $870 in 2025.

$7,516in general payments, 2019–2025

Across 242 payments — averaging $31.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Nevro Corp.$952
  • Abbott$529
  • Saluda Medical Americas, Inc.$413
  • Biotronik NRO, Inc.$305
  • Forte Bio-pharma LLC$269
  • plus $3K from 39 others

What the payments were for

  • Travel & lodging$76710%
  • Food & beverage$6,69789%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,516 in reported general payments places this provider in the 65th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$287,860
Medicare patients
247
Services billed
2,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl100$56,553
Buprenorphine103$22,775
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen937$17,623
OxycontinOxycodone Hcl24$17,596
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen620$15,652
Nucynta ErTapentadol Hcl11$12,749
Xtampza ErOxycodone Myristate28$8,924
Oxycodone Hcl263$4,317
Morphine Sulfate ErMorphine Sulfate202$4,163
Gabapentin204$2,790
Pregabalin162$2,176
Fentanyl29$1,862
Tramadol Hcl ErTramadol Hcl25$1,590
Diclofenac Sodium15$1,146
Tramadol Hcl124$773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Xtampza Er$231$78,226139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 129 interventional pain medicine providers in Georgia.

Other interventional pain medicine in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →